Respiratory Inhaler Selection and Management

Introduction to Inhaler Types and Uses

For most patients with asthma and COPD, metered-dose inhalers (MDIs) with spacers are the first-line choice, as they are equally effective as nebulizers while being more convenient, cost-effective, and efficient, according to the European Respiratory Society 1, 2, 3
MDIs with spacer devices eliminate coordination problems and are equally effective as nebulizers for bronchodilation in both acute exacerbations and stable disease, as recommended by the European Respiratory Society 1, 2, 4

The European Respiratory Society recommends that MDIs with spacers are used for patients with good coordination and inspiratory effort, while nebulizers are used for patients with inadequate inspiratory flow or severe breathlessness 1, 2, 4, 5
Breath-actuated MDIs are available for patients who struggle with coordination between actuation and inhalation, as suggested by the European Respiratory Society 3
Nebulizers convert liquid medication into an aerosol mist and require minimal patient cooperation, making them suitable for patients who cannot use hand-held devices, as recommended by the European Respiratory Society 1, 2, 4, 5

The European Respiratory Society recommends short-acting bronchodilators, such as β2-agonists (e.g., salbutamol 200-400 μg) and anticholinergics (e.g., ipratropium bromide 40-80 μg), for acute exacerbations via MDI or nebulizer 1, 2, 3, 7
For acute exacerbations via nebulizer, the European Respiratory Society recommends salbutamol 2.5-5 mg or terbutaline 5-10 mg, with ipratropium 500 μg added for asthma 1, 2, 7

The European Respiratory Society recommends assessing clinical urgency, evaluating patient capability, determining dose requirements, and considering special medications when selecting an inhaler device 1, 2, 3, 5, 6, 7
For acute severe exacerbation, the European Respiratory Society recommends using a nebulizer or MDI with spacer, as both are equally effective 1, 2, 6
For stable disease, the European Respiratory Society recommends starting with an MDI with spacer 3

The European Respiratory Society recommends always driving nebulizers with air, not oxygen, in patients with CO2 retention to prevent worsening hypercapnia, and providing supplemental oxygen via nasal cannulae at 4 L/min during air-driven nebulization if needed 6, 3, 9
The European Respiratory Society recommends using a mouthpiece rather than a face mask when administering ipratropium to avoid ocular complications and potential glaucoma worsening 1, 7, 6

The European Respiratory Society recommends proper inhaler technique must be demonstrated and checked periodically before modifying treatments, and patients should be changed from nebulizers to hand-held inhalers as soon as their condition stabilizes 3, 7
Disposable nebulizer components should be changed every 3-4 months, with annual compressor servicing, as recommended by the European Respiratory Society 6

The European Respiratory Society recommends never using water for nebulization, as it may cause bronchoconstriction, and not prescribing home nebulizer therapy without formal assessment by a respiratory specialist 3, 8
The European Respiratory Society recommends avoiding combining LABA-containing inhalers with additional LABA medications due to overdose risk, and not assuming nebulizers are superior to MDIs with spacers—they are equally effective when proper technique is used 1, 2, 4
Patients requiring β-agonists should have their first treatment supervised in elderly patients due to potential angina precipitation, as recommended by the European Respiratory Society 6